| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803021701028 | 302170102 | LEVETIRACETAM/ACTAVIS F.C.TAB 250MG/TAB BTx30 σε BLISTERS (alu/PVC) BLISTERS (alu/PVC) | 04.09 | 4.29 | 5.91 |
| 05/2018 | 2803021702025 | 302170202 | LEVETIRACETAM/ACTAVIS F.C.TAB 500MG/TAB BTx30 σε BLISTERS (alu/PVC) BLISTERS (alu/PVC) | 8.17 | 8.57 | 11.81 |
| 05/2018 | 2803021703022 | 302170302 | LEVETIRACETAM/ACTAVIS F.C.TAB 750MG/TAB BTx30 σε BLISTERS (alu/PVC) BLISTERS (alu/PVC) | 7.96 | 8.35 | 11.51 |
| 05/2018 | 2803021704029 | 302170402 | LEVETIRACETAM/ACTAVIS F.C.TAB 1000MG/TAB BTx30 σε BLISTERS (alu/PVC) BLISTERS (alu/PVC) | 16.34 | 17.14 | 23.62 |
Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain. Levetiracetam is thought to stimulate synaptic vesicle protein 2A (SV2A), inhibiting neurotransmitter release.
Side effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing
Rapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.
6-8 hours
Sixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites have no known pharmacological activity and are renally excreted. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.
* 0.96 mL/min/kg